Randomized trial · people

Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, staying on pemvidutide for 24 weeks lowered liver fat more than 12 weeks did, with the 1.8 mg and 2.4 mg arms showing the largest drops.

Kind
Randomized trial
Studied in
People
Number studied
64
Published
2025
Journal
JHEP Rep

What they tested

The team tested whether 12 more weeks of pemvidutide, for 24 weeks in total, would further lower liver fat and body weight in people with MASLD, a fatty liver disease linked to metabolic dysfunction.

How the study was done

A double-blind, placebo-controlled extension of a randomized trial, in which 64 people who finished the first 12 weeks stayed on their original weekly shot of pemvidutide (1.2 mg, 1.8 mg or 2.4 mg) or placebo, a dummy shot, for 12 more weeks. Participants were stratified by type 2 diabetes, meaning those with and without it were grouped separately when assigned.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

After 24 weeks, liver fat fell from its starting level by 56.3% in the 1.2 mg arm, 75.2% in the 1.8 mg arm and 76.4% in the 2.4 mg arm, compared with 14.0% on placebo. Liver fat was measured by MRI-PDFF, an MRI scan that measures the share of the liver that is fat. In the 1.8 mg arm, 84.6% of people cut their liver fat by at least half, and 53.8% reached a normal level of 5% or less. Body weight fell by 6.2% over the 24 weeks, and side effects were uncommon at all doses.

What it doesn’t show

Only people who completed the first 12 weeks entered this extension, and the group was small and followed for only 24 weeks. Liver fat was measured by imaging, so the study does not show effects on long-term liver outcomes.

The paper

Browne et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep. 2025.

The compound

More studies on Pemvidutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo